Haleon Pakistan Limited has revealed a significant leadership change as part of its executive rotation program. The consumer healthcare giant appointed Qawi Naseer as its incoming Chief Executive Officer and Executive Director, effective June 1, 2025.
Transition Timeline:
– April 28, 2025: Naseer joins Haleon Pakistan to begin transition
– May 31, 2025: Current CEO Farhan M. Haroon concludes tenure
– June 1, 2025: Naseer assumes full CEO responsibilities
Executive Movements:
Current leader Farhan M. Haroon will take up a new challenge as General Manager of Haleon South Africa, marking his second international assignment with the British multinational. Haroon, who successfully steered Haleon Pakistan through its demerger from GSK in 2022, will oversee the local subsidiary until the transition date.
About the New Leadership:
Qawi Naseer brings extensive multinational experience in the FMCG and healthcare sectors. His appointment continues Haleon’s practice of developing internal talent for global leadership roles. The incoming CEO faces key challenges including:
– Navigating Pakistan’s evolving OTC healthcare market
– Maintaining growth amid economic pressures
– Continuing Haleon’s digital transformation initiatives
The company has initiated regulatory filings with PUCARS to formalize the leadership change. Industry analysts view this as a routine rotation within Haleon’s global talent pipeline, noting similar recent transitions in other emerging markets.
What This Means:
The transition comes at a pivotal time for Pakistan’s consumer health sector, with Haleon maintaining its market leadership in pain relief (Panadol), vitamins (Emergen-C), and oral care (Sensodyne). Naseer’s appointment suggests continuity in corporate strategy while bringing fresh perspective to local operations.
Market Reaction:
Haleon Pakistan’s stock (PSX: HALEON) held steady after the announcement, showcasing investor confidence in the planned succession. The company’s shares have delivered 18% returns since its PSX debut in July 2022.
